Henrik Zetterberg discusses the use of ultrasensitive biomarker assays from Quanterix for Alzheimer’s research
In The News
SelectScience Interview | January 29, 2018
TheStreet | January 22, 2018
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
GenomeWeb | January 17, 2018
Fresh off a $74 million initial public offering, Quanterix is looking to make immediate inroads in the biotech and pharma research space with longer-term plans to move into diagnostics and health monitoring.
Medical Device and Diagnostic Industry | January 16, 2018
Would you rather get a biopsy or a blood test to check for prostate cancer?
Genetic Engineering & Biotechnology News | January 15, 2018
New technology has shown promise for detecting CTE and the approximately 150 protein biomarkers linked to conditions in neurology, oncology, cardiology, inflammation, and infectious disease. Called Simoa™, it is a single-molecule array on a fully automated digital immunoassay platform that detects…
January 12, 2018
Presentation led by Kevin Hrusovsky, President, Chairman and CEO Quanterix Presentation Date: Wednesday, January 10, 2018